Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application

• Published in: Cancers Vol. 11; no. 7; p. 915
• Main Authors: Mulder, Tom A, Wahlin, Björn E, Österborg, Anders, Palma, Marzia
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 29.06.2019; MDPI
• Subjects: Anergy; Bone marrow; Cancer; Cell survival; Chronic lymphocytic leukemia; Clinical trials; Drug delivery; Drug development; Gene expression; Genotype & phenotype; Hodgkin's lymphoma; Immunosuppressive agents; Inflammation; Lymphatic leukemia; Lymphocytes; Lymphocytes B; Lymphoma; Medical prognosis; Medicin och hälsovetenskap; Review; Reviews; Stromal cells; Tumor microenvironment; Tumors; macrophages; PD-L1; immune cells; CD47; tumor microenvironment; T cells; PD-1; B-cell lymphoma; Hodgkin lymphoma
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers11070915

In lymphomas of B-cell origin, cancer cells orchestrate an inflammatory microenvironment of immune and stromal cells that sustain the tumor cell survival and growth, known as a tumor microenvironment (TME). The features of the TME differ between the different lymphoma types, ranging from extremely inflammatory, such as in Hodgkin lymphoma, to anergic, leading to immune deficiency and susceptibility to infections, such as in chronic lymphocytic leukemia. Understanding the characteristic features of the TME as well as the interactions between cancer and TME cells has given insight into the pathogenesis of most lymphomas and contributed to identify novel therapeutic targets. Here, we summarize the preclinical data that contributed to clarifying the role of the immune cells in the TME of different types of lymphomas of B-cell origin, and explain how the understanding of the biological background has led to new clinical applications. Moreover, we provide an overview of the clinical results of trials that assessed the safety and efficacy of drugs directly targeting TME immune cells in lymphoma patients.